Version: | 0.0.1 |
Date: | 2025-07-17 |
Title: | In Vitro Toxicokinetic Data Processed with the 'invitroTKstats' Pipeline |
Description: | A collection of datasets containing a variety of in vitro toxicokinetic measurements including – but not limited to – chemical fraction unbound in the presence of plasma (f_up), intrinsic hepatic clearance (Clint, uL/min/million hepatocytes), and membrane permeability for oral absorption (Caco2). The datasets provided by the package were processed and analyzed with the companion 'invitroTKstats' package. |
Depends: | R (≥ 3.5.0) |
Imports: | Rdpack |
RdMacros: | Rdpack |
License: | MIT + file LICENSE |
LazyData: | true |
Encoding: | UTF-8 |
RoxygenNote: | 7.3.2 |
URL: | https://github.com/USEPA/invitroTKdata |
BugReports: | https://github.com/USEPA/invitroTKdata/issues |
NeedsCompilation: | no |
Packaged: | 2025-07-31 13:50:35 UTC; SDAVID02 |
Author: | Sarah E. Davidson-Fritz
|
Maintainer: | Sarah E. Davidson-Fritz <davidsonfritz.sarah@epa.gov> |
Repository: | CRAN |
Date/Publication: | 2025-08-19 14:50:07 UTC |
Crizer et al. (2024) Intrinsic Hepatic Clearance Level-2 Data Set
Description
Mass Spectrometry measurements of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocyte suspensions. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr. Crizer.
Usage
crizer2024.clint
Format
A level-2 data.frame with 7,070 rows and 24 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of Clint sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration – usually the date
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area of internal standard (pixels)
Hep.Density
The density (units of millions of hepatocytes per mL) hepatocytes in the in vitro incubation
Std.Conc
Concentration of analytic standard (for calibration curve) (uM)
Clint.Assay.Conc
Intended initial concentration of chemical (uM)
Time
Time when sample was measured (h)
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis)
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level-0 data.frame
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
References
Crizer DM, Rice JR, Smeltz MG, Lavrich KS, Ravindra K, Wambaugh JF, DeVito M, Wetmore BA (2024). “In Vitro Hepatic Clearance Evaluations of Per-and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories.” Toxics, 12(9), 672.
Crizer et al. (2024) Intrinsic Hepatic Clearance Level-3 Data Set
Description
Frequentist estimates of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocyte suspensions. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr. Crizer.
Usage
crizer2024.clint.L3
Format
A level-3 data.frame with 60 rows and 13 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Calibration
Identifier for mass spectrometry calibration – usually the date
Clint
Frequentist point estimate for intrinsic hepatic clearance (Clint)
Clint.pValue
p-value of the estimated
Clint
valueFit
Test nominal concentrations in the linear regression fit
AIC
Akaike Information Criterion (AIC) for the linear regression fit
AIC.Null
Akaike Information Criterion of the exponential decay assuming a constant rate of decay
Clint.1
Intrinsic hepatic clearance at 1 uM (frequentist point estimate)
Clint.10
Intrinsic hepatic clearance at 10 uM (frequentist point estimate)
AIC.Sat
Akaike Information Criterion of the exponential decay with a saturation probability
Sat.pValue
p-value of exponential decay with a saturation probability
References
Crizer DM, Rice JR, Smeltz MG, Lavrich KS, Ravindra K, Wambaugh JF, DeVito M, Wetmore BA (2024). “In Vitro Hepatic Clearance Evaluations of Per-and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories.” Toxics, 12(9), 672.
Crizer et al. (2024) Intrinsic Hepatic Clearance Level-4 Data Set
Description
Bayesian estimates of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocyte suspensions. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr. Crizer.
Usage
crizer2024.clint.L4
Format
A level-4 data.frame with 60 rows and 12 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Clint.1.Med
Posterior median intrinsic hepatic clearance at 1 uM
Clint.1.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 1 uM (lower credible interval bound)
Clint.1.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 1 uM (upper credible interval bound)
Clint.10.Med
Posterior median intrinsic hepatic clearance at 10 uM
Clint.10.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 10 uM (lower credible interval bound)
Clint.10.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 10 uM (upper credible interval bound)
Clint.pValue
Probability that a chemical concentration decrease is observed
Sat.pValue
Probability that a lower
Clint
is observed at a higher concentration, i.e. saturation probabilitydegrades.pValue
Probability of abiotic degradation
References
Crizer DM, Rice JR, Smeltz MG, Lavrich KS, Ravindra K, Wambaugh JF, DeVito M, Wetmore BA (2024). “In Vitro Hepatic Clearance Evaluations of Per-and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories.” Toxics, 12(9), 672.
Kreutz et al. (2023) Intrinsic Hepatic Clearance Level-2 Data Set
Description
Mass Spectrometry measurements of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocyte suspensions. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr.s Anna Kreutz and Barbara Wetmore.
Usage
kreutz2023.clint
Format
A level-2 data.frame with 5,800 rows and 25 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of Clint sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration – usually the date
Std.Conc
Concentration of analytic standard (for calibration curve) (uM)
Clint.Assay.Conc
Intended initial concentration of chemical (uM)
Time
Time when sample was measured (h)
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area of internal standard (pixels)
Hep.Density
The density (units of millions of hepatocytes per mL) hepatocytes in the in vitro incubation
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis)
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level-0 data.frame
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Kreutz A, Clifton MS, Henderson WM, Smeltz MG, Phillips M, Wambaugh JF, Wetmore BA (2023). “Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry.” Toxics, 11(5), 463.
Kreutz et al. (2023) Intrinsic Hepatic Clearance Level-3 Data Set
Description
Frequentist estimates of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocyte suspensions. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr.s Anna Kreutz and Barbara Wetmore.
Usage
kreutz2023.clint.L3
Format
A level-3 data.frame with 25 rows and 13 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Calibration
Identifier for mass spectrometry calibration – usually the date
Clint
Frequentist point estimate for intrinsic hepatic clearance (Clint)
Clint.pValue
p-value of the estimated
Clint
valueFit
Test nominal concentrations in the linear regression fit
AIC
Akaike Information Criterion (AIC) for the linear regression fit
AIC.Null
Akaike Information Criterion of the exponential decay assuming a constant rate of decay
Clint.1
Intrinsic hepatic clearance at 1 uM (frequentist point estimate)
Clint.10
Intrinsic hepatic clearance at 10 uM (frequentist point estimate)
AIC.Sat
Akaike Information Criterion of the exponential decay with a saturation probability
Sat.pValue
p-value of exponential decay with a saturation probability
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Kreutz A, Clifton MS, Henderson WM, Smeltz MG, Phillips M, Wambaugh JF, Wetmore BA (2023). “Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry.” Toxics, 11(5), 463.
Kreutz et al. (2023) Intrinsic Hepatic Clearance Level-4 Data Set
Description
Bayesian estimates of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocyte suspensions. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr.s Anna Kreutz and Barbara Wetmore.
Usage
kreutz2023.clint.L4
Format
A level-4 data.frame with 25 rows and 12 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Clint.1.Med
Posterior median intrinsic hepatic clearance at 1 uM
Clint.1.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 1 uM (lower credible interval bound)
Clint.1.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 1 uM (upper credible interval bound)
Clint.10.Med
Posterior median intrinsic hepatic clearance at 10 uM
Clint.10.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 10 uM (lower credible interval bound)
Clint.10.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 10 uM (upper credible interval bound)
Clint.pValue
Probability that a chemical concentration decrease is observed
Sat.pValue
Probability that a lower
Clint
is observed at a higher concentration, i.e. saturation probabilitydegrades.pValue
Probability of abiotic degradation
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Kreutz A, Clifton MS, Henderson WM, Smeltz MG, Phillips M, Wambaugh JF, Wetmore BA (2023). “Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry.” Toxics, 11(5), 463.
Kreutz et al. (2023) Ultracentrifugation Level-2 Data Set
Description
Mass Spectrometry measurements of plasma protein binding measured by ultracentrifugation (UC) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Anna Kreutz and Barbara Wetmore.
Usage
kreutz2023.uc
Format
A level-2 data.frame with 2,955 rows and 23 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of UC sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration – usually the date
Standard.Conc
Concentration of analytic standard (for calibration curve) (uM)
UC.Assay.T1.Conc
Intended concentration of chemical intended in T1 sample (uM)
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area of internal standard (pixels)
Series
Identier for replicate series of UC measurements
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level-0 data.frame
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
References
Howard ML, Hill JJ, Galluppi GR, McLean MA (2010). “Plasma protein binding in drug discovery and development.” Combinatorial chemistry & high throughput screening, 13(2), 170–187.
Kreutz A, Clifton MS, Henderson WM, Smeltz MG, Phillips M, Wambaugh JF, Wetmore BA (2023). “Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry.” Toxics, 11(5), 463.
Kreutz et al. (2023) Ultracentrifugation Level-3 Data Set
Description
Frequentist estimates of plasma protein binding measured by ultracentrifugation (UC) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Anna Kreutz and Barbara Wetmore.
Usage
kreutz2023.uc.L3
Format
A level-3 data.frame with 73 rows and 5 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Calibration
Identifier for mass spectrometry calibration – usually the date
Fup
Frequentist point estimate for fraction unbound in plasma (fup)
References
Howard ML, Hill JJ, Galluppi GR, McLean MA (2010). “Plasma protein binding in drug discovery and development.” Combinatorial chemistry & high throughput screening, 13(2), 170–187.
Kreutz A, Clifton MS, Henderson WM, Smeltz MG, Phillips M, Wambaugh JF, Wetmore BA (2023). “Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry.” Toxics, 11(5), 463.
Kreutz et al. (2023) Ultracentrifugation Level-4 Data Set
Description
Bayesian estimates of plasma protein binding measured by ultracentrifugation (UC) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Anna Kreutz and Barbara Wetmore.
Usage
kreutz2023.uc.L4
Format
A level-4 data.frame with 52 rows and 13 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Fstable.Med
Posterior median chemical stability fraction
Fstable.Low
Posterior 2.5th quantile chemical stability fraction (lower credible interval bound)
Fstable.High
Posterior 97.5th quantile chemical stability fraction (upper credible interval bound)
Fup.Med
Posterior median fraction unbound in plasma
Fup.Low
Posterior 2.5th quantile of fraction unbound in plasma (lower credible interval bound)
Fup.High
Posterior 97.5th quantile of fraction unbound in plasma (upper credible interval bound)
Fup.point
Point estimate of fraction unbound in plasma
Unstable
Qualitative determination of chemical stability. "Y" indicates observed chemical stability.
Uncertain
Qualitative determination of uncertainty about chemical stability. "Y" indicates uncertainty in observed chemical stability.
CV
Coefficient of variance
References
Howard ML, Hill JJ, Galluppi GR, McLean MA (2010). “Plasma protein binding in drug discovery and development.” Combinatorial chemistry & high throughput screening, 13(2), 170–187.
Kreutz A, Clifton MS, Henderson WM, Smeltz MG, Phillips M, Wambaugh JF, Wetmore BA (2023). “Category-Based Toxicokinetic Evaluations of Data-Poor Per- and Polyfluoroalkyl Substances (PFAS) using Gas Chromatography Coupled with Mass Spectrometry.” Toxics, 11(5), 463.
Smeltz et al. (2023) Intrinsic Hepatic Clearance Level-2 Data Set
Description
Mass Spectrometry measurements of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocytes. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.clint
Format
A level-2 data.frame with 625 rows and 24 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of Clint sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration – usually the date
Std.Conc
Concentration of analytic standard (for calibration curve) (uM)
Clint.Assay.Conc
Intended initial concentration of chemical (uM)
Time
Time when sample was measured (h)
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area of internal standard (pixels)
Hep.Density
The density (units of millions of hepatocytes per mL) hepatocytes in the in vitro incubation
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level0 data table)
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Intrinsic Hepatic Clearance Level-3 Data Set
Description
Frequentist estimate of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocytes. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.clint.L3
Format
A level-3 data.frame with 6 rows and 13 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Calibration
Identifier for mass spectrometry calibration – usually the date
Clint
Frequentist point estimate for intrinsic hepatic clearance (Clint)
Clint.pValue
p-value of the estimated
Clint
valueFit
Test nominal concentrations in the linear regression fit
AIC
Akaike Information Criterion (AIC) for the linear regression fit
AIC.Null
Akaike Information Criterion of the exponential decay assuming a constant rate of decay
Clint.1
Intrinsic hepatic clearance at 1 uM (frequentist point estimate)
Clint.10
Intrinsic hepatic clearance at 10 uM (frequentist point estimate)
AIC.Sat
Akaike Information Criterion of the exponential decay with a saturation probability
Sat.pValue
p-value of exponential decay with a saturation probability
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Intrinsic Hepatic Clearance Level-4 Data Set
Description
Bayesian estimate of intrinsic hepatic clearance (Clint) for cryopreserved pooled human hepatocytes. Chemicals were per- and polyfluoroalkyl substance (PFAS) samples. The experiments were led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.clint.L4
Format
A level-4 data.frame with 7 rows and 12 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Clint.1.Med
Posterior median intrinsic hepatic clearance at 1 uM
Clint.1.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 1 uM (lower credible interval bound)
Clint.1.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 1 uM (upper credible interval bound)
Clint.10.Med
Posterior median intrinsic hepatic clearance at 10 uM
Clint.10.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 10 uM (lower credible interval bound)
Clint.10.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 10 uM (upper credible interval bound)
Clint.pValue
Probability that a chemical concentration decrease is observed
Sat.pValue
Probability that a lower
Clint
is observed at a higher concentration, i.e. saturation probabilitydegrades.pValue
Probability of abiotic degradation
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Rapid Equilibrium Dialysis Level-2 Data Set
Description
Mass Spectrometry measurements of plasma protein binding measured by rapid equilibrium dialysis (RED) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.red
Format
A level-2 data.frame with 3,955 rows and 25 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of RED sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration – usually the date
Std.Conc
Concentration of analytic standard (for calibration curve) (uM)
Test.Nominal.Conc
Intended concentration of chemical introduced into RED plate (uM)
Percent.Physiologic.Plasma
Percent of physiological plasma concentration in RED plate (in percent)
Time
Time of sample measurement (h)
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area of internal standard (pixels)
Replicate
Identifier for replicate series of RED measurements
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level-0 data.frame
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
References
Waters NJ, Jones R, Williams G, Sohal B (2008). “Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.” Journal of pharmaceutical sciences, 97(10), 4586–4595.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Rapid Equilibrium Dialysis Level-3 Data Set
Description
Frequentist estimate of plasma protein binding measured by rapid equilibrium dialysis (RED) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.red.L3
Format
A level-3 data.frame with 15 rows and 4 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Calibration
Identifier for mass spectrometry calibration – usually the date
Fup
Frequentist point estimate for fraction unbound in plasma (fup)
References
Waters NJ, Jones R, Williams G, Sohal B (2008). “Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.” Journal of pharmaceutical sciences, 97(10), 4586–4595.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Rapid Equilibrium Dialysis Level-4 Data Set
Description
Bayesian estimate of plasma protein binding measured by rapid equilibrium dialysis (RED) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.red.L4
Format
A level-4 data.frame with 15 rows and 7 variables:
Compound.Name
Compound name
Lab.Compound.Name
Compound as described in the laboratory
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Fup.point
Point estimate of fraction unbound in plasma
Fup.Med
Posterior median estimate of fraction unbound in plasma
Fup.Low
Posterior 2.5th quantile of fraction unbound in plasma (lower credible interval bound)
Fup.High
Posterior 97.5th quantile of fraction unbound in plasma (upper credible interval bound)
References
Waters NJ, Jones R, Williams G, Sohal B (2008). “Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.” Journal of pharmaceutical sciences, 97(10), 4586–4595.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Ultracentrifugation Level-2 Data Set
Description
Mass Spectrometry measurements of plasma protein binding measured by ultracentrifugation (UC) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.uc
Format
A level-2 data.frame with 10,133 rows and 23 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of UC sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration – usually the date
Standard.Conc
Concentration of analytic standard (for calibration curve) (uM)
UC.Assay.T1.Conc
Intended concentration of chemical in T1 sample (uM)
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area of internal standard (pixels)
Series
Identifier for replicate series of UC measurements
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level-0 data.frame
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
References
Howard ML, Hill JJ, Galluppi GR, McLean MA (2010). “Plasma protein binding in drug discovery and development.” Combinatorial chemistry & high throughput screening, 13(2), 170–187.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Ultracentrifugation Level-3 Data Set
Description
Frequentist estimate of plasma protein binding measured by ultracentrifugation (UC) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.uc.L3
Format
A level-3 data.frame with 107 rows and 5 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Calibration
Identifier for mass spectrometry calibration – usually the date
Fup
Frequentist point estimate for fraction unbound in plasma (fup)
References
Howard ML, Hill JJ, Galluppi GR, McLean MA (2010). “Plasma protein binding in drug discovery and development.” Combinatorial chemistry & high throughput screening, 13(2), 170–187.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Smeltz et al. (2023) Ultracentrifugation Level-4 Data Set
Description
Bayesian estimate of plasma protein binding measured by ultracentrifugation (UC) for per- and poly-fluorinated alkyl substance (PFAS) samples from experiments led by Dr.s Marci Smeltz and Barbara Wetmore.
Usage
smeltz2023.uc.L4
Format
A level-4 data.frame with 69 rows and 7 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Fup.Med
Posterior median fraction unbound in plasma
Fup.Low
Posterior 2.5th quantile of fraction unbound in plasma (lower credible interval bound)
Fup.High
Posterior 97.5th quantile of fraction unbound in plasma (upper credible interval bound)
Fup.point
Point estimate of fraction unbound in plasma
References
Howard ML, Hill JJ, Galluppi GR, McLean MA (2010). “Plasma protein binding in drug discovery and development.” Combinatorial chemistry & high throughput screening, 13(2), 170–187.
Smeltz M, Wambaugh JF, Wetmore BA (2023). “Plasma Protein Binding Evaluations of Per- and Polyfluoroalkyl Substances for Category-Based Toxicokinetic Assessment.” Chemical Research in Toxicology, 36(6), 870–881.
Wambaugh et al. (2019) Intrinsic Hepatic Clearance Level-2 Data Set
Description
Mass spectrometry measurements of intrinsic hepatic clearance (Clint) measured using in vitro suspensions of pooled primary human hepatocytes (Shibata et al. 2002).
Usage
wambaugh2019.clint
Format
A data.frame with 22898 rows and 26 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of Clint sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration – usually the date
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area of internal standard (pixels)
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level-0 data.frame
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Time
Time when sample was measured (h)
Test.Compound.Conc
Measured concentration of analytic standard (for calibration curve) (uM)
Test.Nominal.Conc
Expected initial concentration of chemical added to donor side (uM)
Hep.Density
The density (units of millions of hepatocytes per mL) hepatocytes in the in vitro incubation
Biological.Replicates
Identifier for measurements of multiple samples with the same analyte
Technical.Replicates
Identifier for measurements of one sample of a compound
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
Source
Wambaugh et al. (2019)
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Wambaugh JF, Wetmore BA, Ring CL, Nicolas CI, Pearce RG, Honda GS, Dinallo R, Angus D, Gilbert J, Sierra T, others (2019). “Assessing toxicokinetic uncertainty and variability in risk prioritization.” Toxicological Sciences, 172(2), 235–251.
Wambaugh et al. (2019) Intrinsic Hepatic Clearance Level-3 Data Set
Description
Frequentist estimate of intrinsic hepatic clearance (Clint) measured using in vitro suspensions of pooled primary human hepatocytes (Shibata et al. 2002).
Usage
wambaugh2019.clint.L3
Format
A data.frame with 473 rows and 13 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemical Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Calibration
Identifier for mass spectrometry calibration - usually the date
Clint
Frequentist point estimate for intrinsic hepatic clearance (Clint)
Clint.pValue
p-value of the estimated
Clint
valueFit
Test nominal concentrations in the linear regression fit
AIC
Akaike Information Criterion (AIC) for the linear regression fit
AIC.Null
Akaike Information Criterion of the exponential decay assuming a constant rate of decay
Clint.1
Intrinsic hepatic clearance at 1 uM (frequentist point estimate)
Clint.10
Intrinsic hepatic clearance at 10 uM (frequentist point estimate)
AIC.Sat
Akaike Information Criterion of the exponential decay with a saturation probability
Sat.pValue
p-value of exponential decay with a saturation probability
Source
Wambaugh et al. (2019)
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Wambaugh JF, Wetmore BA, Ring CL, Nicolas CI, Pearce RG, Honda GS, Dinallo R, Angus D, Gilbert J, Sierra T, others (2019). “Assessing toxicokinetic uncertainty and variability in risk prioritization.” Toxicological Sciences, 172(2), 235–251.
Wambaugh et al. (2019) Intrinsic Hepatic Clearance Level-4 Data Set
Description
Bayesian estimate of intrinsic hepatic clearance (Clint) measured using in vitro suspensions of pooled primary human hepatocytes (Shibata et al. 2002).
Usage
wambaugh2019.clint.L4
Format
A level-4 data.frame with 473 rows and 12 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Clint.1.Med
Posterior median intrinsic hepatic clearance at 1 uM
Clint.1.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 1 uM (lower credible interval bound)
Clint.1.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 1 uM (upper credible interval bound)
Clint.10.Med
Posterior median intrinsic hepatic clearance at 10 uM
Clint.10.Low
Posterior 2.5th quantile of intrinsic hepatic clearance at 10 uM (lower credible interval bound)
Clint.10.High
Posterior 97.5th quantile of intrinsic hepatic clearance at 10 uM (upper credible interval bound)
Clint.pValue
Probability that a chemical concentration decrease is observed
Sat.pValue
Probability that a lower
Clint
is observed at a higher concentration, i.e. saturation probabilitydegrades.pValue
Probability of abiotic degradation
Source
Wambaugh et al. (2019)
References
Shibata Y, Takahashi H, Chiba M, Ishii Y (2002). “Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method.” Drug Metabolism and disposition, 30(8), 892–896.
Wambaugh JF, Wetmore BA, Ring CL, Nicolas CI, Pearce RG, Honda GS, Dinallo R, Angus D, Gilbert J, Sierra T, others (2019). “Assessing toxicokinetic uncertainty and variability in risk prioritization.” Toxicological Sciences, 172(2), 235–251.
Wambaugh et al. (2019) Rapid Equilibrium Dialysis Level-2 Data Set
Description
Mass spectrometry measurements of plasma protein binding using the rapid equilibrium dialysis (RED) assay method (Waters et al. 2008).
Usage
wambaugh2019.red
Format
A data.frame 15990 rows and 26 variables:
Lab.Sample.Name
Sample description used in the laboratory
Date
Date sample was acquired
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Lab.Compound.Name
Compound as described in the laboratory
Sample.Type
Type of RED sample
Dilution.Factor
Number of times the sample was diluted
Calibration
Identifier for mass spectrometry calibration - usually the date
ISTD.Name
Name of compound used as internal standard (ISTD)
ISTD.Conc
Concentration of ISTD (uM)
ISTD.Area
Peak area internal standard (pixels)
Area
Peak area of analyte (target compound)
Analysis.Method
General description of chemical analysis method
Analysis.Instrument
Instrument(s) used for chemical analysis
Analysis.Parameters
Parameters for identifying analyte peak (for example, retention time)
Note
Any laboratory notes about sample
Level0.File
Name of data file from laboratory that was used to compile level-0 data.frame
Level0.Sheet
Name of "sheet" (for Excel workbooks) from which the laboratory data were read
Time
Time when sample was measured (h)
Test.Compound.Conc
Measured concentration of analytic standard (for calibration curve) (uM)
Test.Nominal.Conc
Expected initial concentration of chemical added to donor side (uM)
Percent.Physiologic.Plasma
Percent of physiology plasma concentration in RED plate (in percent)
Biological.Replicates
Identifier for measurements of multiple samples with the same analyte
Technical.Replicates
Identifier for measurements of one sample of a compound
Response
Response factor (calculated from analyte and ISTD peaks)
Verified
If "Y", then sample is included in the analysis. (Any other value causes the data to be ignored.)
Source
Wambaugh et al. (2019)
References
Waters NJ, Jones R, Williams G, Sohal B (2008). “Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.” Journal of pharmaceutical sciences, 97(10), 4586–4595.
Wambaugh JF, Wetmore BA, Ring CL, Nicolas CI, Pearce RG, Honda GS, Dinallo R, Angus D, Gilbert J, Sierra T, others (2019). “Assessing toxicokinetic uncertainty and variability in risk prioritization.” Toxicological Sciences, 172(2), 235–251.
Wambaugh et al. (2019) Rapid Equilibrium Dialysis Level-3 Data Set
Description
Frequentist estimate of plasma protein binding using the rapid equilibrium dialysis (RED) assay method (Waters et al. 2008).
Usage
wambaugh2019.red.L3
Format
A data.frame 368 rows and 4 variables:
Compound.Name
Compound name
DTXSID
DSSTox Substance Identifier (CompTox Chemicals Dashboard)
Calibration
Identifier for mass spectrometry calibration - usually the date
Fup
Frequentist point estimate for fraction unbound in plasma (fup)
Source
Wambaugh et al. (2019)
References
Waters NJ, Jones R, Williams G, Sohal B (2008). “Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.” Journal of pharmaceutical sciences, 97(10), 4586–4595.
Wambaugh JF, Wetmore BA, Ring CL, Nicolas CI, Pearce RG, Honda GS, Dinallo R, Angus D, Gilbert J, Sierra T, others (2019). “Assessing toxicokinetic uncertainty and variability in risk prioritization.” Toxicological Sciences, 172(2), 235–251.
Wambaugh et al. (2019) Rapid Equilibrium Dialysis Level-4 Data Set
Description
Bayesian estimate of plasma protein binding using the rapid equilibrium dialysis (RED) assay method (Waters et al. 2008).
Usage
wambaugh2019.red.L4
Format
A data.frame 301 rows and 7 variables:
Compound.Name
Compound name
Lab.Compound.Name
Compound as described in the laboratory
DTXSID
DSSTox Substance Identifier (CompTox Chemical Dashboard)
Fup.point
Point estimate of fraction unbound in plasma
Fup.Med
Posterior median fraction unbound in plasma
Fup.Low
Posterior 2.5th quantile of fraction unbound in plasma (lower credible interval bound)
Fup.High
Posterior 97.5th quantile of fraction unbound in plasma (upper credible interval bound)
Source
Wambaugh et al. (2019)
References
Waters NJ, Jones R, Williams G, Sohal B (2008). “Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.” Journal of pharmaceutical sciences, 97(10), 4586–4595.
Wambaugh JF, Wetmore BA, Ring CL, Nicolas CI, Pearce RG, Honda GS, Dinallo R, Angus D, Gilbert J, Sierra T, others (2019). “Assessing toxicokinetic uncertainty and variability in risk prioritization.” Toxicological Sciences, 172(2), 235–251.